Published on Friday, October 29, 2010 FDA said in briefing documents posted ahead of the Vaccines and Related Biological Products Advisory Committee meeting on Nov. 17 that data support approval of Gardasil HPV vaccine from Merck & Co. Inc. (NYSE:MRK) to prevent anal intraepithelial neoplasia (AIN) and anal cancer caused by HPV types 6, […]
FDA: Gardasil approved to prevent anal cancer
FDA Press Release 22 December 2010 The U.S. Food and Drug Administration today approved the vaccine Gardasil for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus (HPV) types 6, 11, 16, and 18 in people ages 9 through 26 years. Gardasil is already approved for the same age […]
HPV Testing for Patients with Atypical Squamous Cells Identifies Those at High Risk for Cancer
By: Barbara Boughton 02 November 2010 (San Francisco, California) — A new study from an inner-city hospital in Atlanta, Georgia, of 348 patients with a diagnosis of atypical squamous cells of undetermined significance (ASC-US) confirms that high-risk human papillomavirus (HPV) assay testing is essential for pinpointing patients with high-grade dysplasia who need follow-up treatment, according […]
